Article
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.
Familial cancer - 1 Jun 2010
Vahteristo Pia, Koski Taru A, Näätsaari Laura, Kiuru Maija, Karhu Auli, Herva Riitta, Sallinen Satu-Leena, Vierimaa Outi, Björck Erik, Richard Stéphane, Gardie Betty, Bessis Didier, Van Glabeke Emmanuel, Blanco Ignacio, Houlston Richard, Senter Leigha, Hietala Marja, Aittomäki Kristiina, Aaltonen Lauri A, Launonen Virpi, Lehtonen Rainer
Abstract excerpt
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumor predisposition syndrome caused by heterozygous germline mutations in the fumarate hydratase (FH) gene. Cutaneous and uterine leiomyomas are the most common clinical manifestations of HLRCC, whereas only approximately 20% of the families display renal cell cancer (RCC). The number of RCC cases in these families varies from one to five....
Topics
- Adult
- Aged, 80 and over
- Carcinoma, Renal Cell
- DNA Mutational Analysis
- Evidence-Based Medicine
- Female
- Finland
- Fumarate Hydratase
- Genetic Association Studies